Major depressive disorder (MDD) is severely disabling, and current treatments have limited
efficacy. The glutamate N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine was …

Evidence from clinical, preclinical, and post-mortem studies supports the
inflammatory/immune hypothesis of schizophrenia pathogenesis. Less evident is the link …

Objective: The authors conducted a systematic review and meta-analysis of ketamine and
other N-methyl-d-aspartate (NMDA) receptor antagonists in the treatment of major …

The enormous diversity of proteoforms produces tremendous complexity within cellular
proteomes, facilitates intricate networks of molecular interactions, and constitutes a …

Considerable recent attention has focused on the rapid antidepressant effects observed in
treatment resistant patients produced by the NMDA receptor antagonist, ketamine …

Schizophrenia is a severe psychiatric disorder with multi-factorial characteristics. A number
of findings have shown disrupted synaptic connectivity in schizophrenia patients and …

Ketamine is an antidepressant with rapid therapeutic onset and long-lasting effect, although
the underlying mechanism (s) remain unknown. Using FRET-based nanosensors we found …

In the brain, astrocytes signal to neighboring cells via regulated exocytotic release of
gliosignaling molecules, such as brain-derived neurotrophic factor (BDNF). Recent studies …

Background Ketamine and psychedelics have abuse liability. They can also induce
“transformative experiences” where individuals experience enhanced states of awareness …

Abstract Prohibitin 1 (PHB1) and prohibitin 2 (PHB2) are proteins that are nearly
ubiquitously expressed. They are localized in mitochondria, cytosol and cell nuclei. In the …